JPH0413352B2 - - Google Patents
Info
- Publication number
- JPH0413352B2 JPH0413352B2 JP27013184A JP27013184A JPH0413352B2 JP H0413352 B2 JPH0413352 B2 JP H0413352B2 JP 27013184 A JP27013184 A JP 27013184A JP 27013184 A JP27013184 A JP 27013184A JP H0413352 B2 JPH0413352 B2 JP H0413352B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- ditetrazolium
- hydrogen
- measuring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 36
- -1 tetrazolium compound Chemical class 0.000 claims description 30
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical group C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- BAWFJGJZGIEFAR-DQQFMEOOSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)O[P@@](O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-DQQFMEOOSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 21
- 238000005259 measurement Methods 0.000 description 18
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 18
- 238000002835 absorbance Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 125000003831 tetrazolyl group Chemical group 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000004040 coloring Methods 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 5
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 5
- 229920004896 Triton X-405 Polymers 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229950006238 nadide Drugs 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 108020005199 Dehydrogenases Proteins 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ZAJAQTYSTDTMCU-UHFFFAOYSA-N 3-aminobenzenesulfonic acid Chemical compound NC1=CC=CC(S(O)(=O)=O)=C1 ZAJAQTYSTDTMCU-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010089254 Cholesterol oxidase Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 150000003536 tetrazoles Chemical group 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- JDDOQUCBYLZDQE-UHFFFAOYSA-N 1,2-diphenyltetrazol-1-ium Chemical compound C=1C=CC=CC=1[N+]1=CN=NN1C1=CC=CC=C1 JDDOQUCBYLZDQE-UHFFFAOYSA-N 0.000 description 1
- HUWXDEQWWKGHRV-UHFFFAOYSA-N 3,3'-Dichlorobenzidine Chemical compound C1=C(Cl)C(N)=CC=C1C1=CC=C(N)C(Cl)=C1 HUWXDEQWWKGHRV-UHFFFAOYSA-N 0.000 description 1
- ZTQGWROHRVYSPW-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZTQGWROHRVYSPW-UHFFFAOYSA-N 0.000 description 1
- MHENYUIEHPSOIA-UHFFFAOYSA-N 4-acetyl-3-aminobenzenesulfonyl chloride Chemical compound C(C)(=O)C1=C(C=C(C=C1)S(=O)(=O)Cl)N MHENYUIEHPSOIA-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- CIWBSHSKHKDKBQ-MVHIGOERSA-N D-ascorbic acid Chemical compound OC[C@@H](O)[C@@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-MVHIGOERSA-N 0.000 description 1
- 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 description 1
- 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 239000012992 electron transfer agent Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- GKQWYZBANWAFMQ-UHFFFAOYSA-M lithium;2-hydroxypropanoate Chemical compound [Li+].CC(O)C([O-])=O GKQWYZBANWAFMQ-UHFFFAOYSA-M 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
(ã€) ç£æ¥äžã®å©çšåé
æ¬çºæã¯ãæ°èŠæ°Žæº¶æ§ãžããã©ãŸãªãŠã ååç©
ããã³ãã®ååç©ãçšããéå
æ§ç©è³ªã®æž¬å®æ¹æ³
ã«é¢ããããã«è©³ããã¯ãïŒïŒ3â²âïŒïŒïŒ3â²âãž
ããâïŒïŒ4â²âãžããšãã¬ã³ïŒâãã¹ïŒïŒïŒïŒâ
ãžããšãã«â2Hâããã©ãŸãªãŠã ïŒã®ããšãã«
åºã«ã¹ã«ãã¢ã¢ã€ã«åºãä»ããŠïŒåã®ã¹ã«ãã³é
ž
åºãæããããšãç¹åŸŽãšãã氎溶æ§ã®ãžããã©ãŸ
ãªãŠã ååç©ããã³ãããçšããéå
æ§ç©è³ªã®æž¬
å®æ¹æ³ã«é¢ããã
ããã©ãŸãªãŠã ååç©ã¯ãè±æ°ŽçŽ é
µçŽ ã®æŽ»æ§åºŠ
ã®æž¬å®ãããã«ããåºè³ªãããã«ã¹ãŒããŒãªããµ
ã€ãã€ãªã³ãçæããé
žåé
µçŽ ã®äœçšå¯Ÿè±¡ã§ãã
åºè³ªã®æž¬å®ãããªãã¡é£åäžã®æ·»å ç©ã®å®éãã
ããã¯çäœäœæ¶²æåã®èšåºè©Šè¬ãšããŠå®çšåãã
ãŠããã
(ã) åŸæ¥ã®æè¡
氎溶æ§ããã©ãŸãªãŠã ååç©ã¯ããããéå
ã
ãæã«çæãããã«ãã¶ã³ãå®å®ãªæ°Žæº¶æ§ååç©
ã§ããã®ã§ããã®ãã«ãã¶ã³ãå®éããããšã«ã
ã氎溶液äžã®éå
æ§ç©è³ªã枬å®ããããšã«å©çšã
ããã
åŸæ¥ããã©ãŸãªãŠã ååç©ãšããŠã¯ãäŸãã°ïŒ
âïŒïŒâãšãŠåããšãã«ïŒâïŒâïŒïŒâãããããš
ãã«ïŒâïŒâããšãã«â2Hâããã©ãŸãªãŠã å¡©
ïŒINTïŒãïŒâïŒïŒïŒïŒâãžã¡ãã«ãã¢ãŸãªã«â
ïŒïŒâïŒïŒïŒâãžããšãã«â2Hâããã©ãŸãªãŠã
å¡©ïŒMTTïŒãïŒïŒ2â²ïŒïŒïŒ5â²âããã©ãã¹ïŒïŒâ
ãããããšãã«ïŒâïŒïŒ3â²âïŒïŒïŒ3â²âãžã¡ããã·
âïŒïŒ4â²âãžããšãã¬ã³ïŒâ2HïŒ2â²Hâãžããã©
ãŸãªãŠã å¡©ïŒNTBïŒãïŒïŒ2â²âïœâãžããšãã¬ã³
âïŒïŒ3â²ïŒïŒïŒ5â²âããã©ããšãã«â2HïŒ2â²Hâ
ãžããã©ãŸãªãŠã å¡©ïŒNeoâTBïŒãªã©ã代衚ç
ã«å©çšãããŠãããããããªããããããããã©
ãŸãªãŠã å¡©åã³ãã®éå
äœã§ãããã«ãã¶ã³ã¯ã
ãããæ°Žã«é£æº¶æ§ã§ããã䜿çšã«ãããå€éã®ç
é¢æŽ»æ§å€ãããã¯ææ©æº¶å€ã®äœµçšããããªãè¡ã€
ãŠããã®ãçŸç¶ã§ãããç¹ã«èšåºæ€æ»ã®åéã§ã¯
çæããããã«ãã¶ã³ã枬å®æ©åšã®æž¬å
éšäœã«è²
çŽ æ²çãçããèããæ€æ»çµæã«æªåœ±é¿ãäžããŠ
ãããåãè¿å¹Žæ¥éã«é²æ©ããæ€æ»ã®èªååã«å¯Ÿ
ããèªååææ©ã®æ±æã«ãã誀枬å®ããŸãããŠã
ãã
以äžã®ãããªçç±ã§ãããã©ãŸãªãŠã å¡©ã䜿çš
ããããšã奜ãŸããæ€æ»é
ç®ã®å Žåã§ããããã
ããä»ã®æž¬å®åçã䜿çšããããšã匷ããããŠã
ãã
ãã®ãããªç¶æ³ã«å¯ŸããŠãç¹å
¬æ56â38154å·ã
ç¹éæ56â61366å·ãç¹éæ56â61367å·ã®åç¹èš±
å
¬å ±ãæ¥æ¬è¬åŠäŒ102幎äŒè¬æŒèŠæšé341é 4K2â
ïŒçã«é瀺ãããããã«ãããã©ãŸãŒã«ç°ã«çœ®æ
ããããšãã«åºã«ãçŽæ¥ã¹ã«ãã³é
žåºãããã¯ã«
ã«ãã³é
žåºãåã¯åçŽã¢ã³ã¢ããŠãŠã å¡©ãå«ãåŽ
éãå°å
¥ããè©Šã¿ããªãããŠããã
ããããå¯æº¶åã®ç®çã§ããšãã«åºã«çŽæ¥å°å
¥
ããããããé
žåºã®ããã«ãå®éã®æž¬å®ã§äžå¯æ¬
ãªé
µçŽ æ©èœãçºæ®ãããè³é©PHåå
ã«ãããŠã¯ã
ãããã®ããã©ãŸãªãŠã ååç©ã¯ãã«ãã¶ã³ãç
ããªãã®ã§èšåºæ€æ»ã®åéã§ã¯å¿çšå°é£ã§ããã
åãåçŽã¢ã³ã¢ããŠãŠã å¡©å°å
¥ååç©ã¯æ°Žæº¶æ§ã®
ç¹ã§äžååã§ããã
åãæè¿ã§ã¯ç¹éæ59â106476å·å
¬å ±ã«ç€ºãã
ãããã«ãããšãã«åºã«çŽæ¥çµåããªã氎溶æ§åº
ïŒã¹ã«ãã³é
žåºåã¯ïŒããã³ã«ã«ãã³é
žåºïŒïŒå
ãå«æãããæ¹æ³ãè©Šã¿ãããŠããã
ããããªãããããã§ææ¡ãããããã©ãŸãªãŠ
ã ååç©ã®éå
åã§ãããã«ãã¶ã³ã¯PHã®å€åã§
èããåååžå
ä¿æ°ãå€åããã
é
µçŽ åå¿ãåæ¢ãããããã«ãèšåºæ€æ»ã§ã¯
é
žãåã¯ã¢ã«ã«ãªã«åå¿æ¶²ã®PHã移è¡ãããæ¹æ³
ãäžè¬çã§ããããããã§ææ¡ãããããã©ãŸãª
ãŠã ååç©ãçšããå Žåãèãã枬å®æ床ãäœäž
ããããæ¬ ç¹ãæããŠããã
(ã) çºæã解決ããããšããŠããåé¡ç¹
æ¬çºæè
ãã¯ããã®ãããªåŸæ¥ã®æ¬ ç¹ã解決ã
ãããã«ã¯ãããã©ãŸãªãŠã ååç©ãæ°Žæ溶æ§ã§
ããããšãéå
ãåãããšãã«ã¯PHäŸåæ§ã®å°ã
ãããšãç¹ã«èšåºæ€æ»ã«äœ¿çšãããå Žåã«ã¯éå
åãã³ãã³é
žã¢ããã¢ããã³ãžãã¯ã¬ãªããïŒä»¥
äžãNADHãšç¥èšãïŒãŸãã¯éå
åãã³ãã³é
žã¢
ãããžãã¯ã¬ãªããçé
žïŒä»¥äžãNADPHãšç¥
èšãïŒã«ããç¹ç°çã«äœçšãããããšãçæãã
ãã«ãã¶ã³ååç©ãæ°Žæ溶æ§ã§ãªããã°ãªããªã
ããšãªã©ã«çç®ããæ€èšãè¡ã€ãçµæãæ¬çºæã
å®æããã«è³ã€ãã
ããªãã¡ãæ¬çºæã®ç¬¬äžã®ç®çã¯ãéå
æ§ç©è³ª
ã«ãã€ãŠãé»åäŒéå€ã®ååšäžã«æ°Žæ溶æ§ã®çºè²
ãã«ãã¶ã³ãçæããæ°èŠãªæ°Žæº¶æ§ããã©ãŸãªãŠ
ã ååç©ãæäŸããããšã§ããã
æ¬çºæã®ç¬¬äºã®ç®çã¯ãæ°èŠãªããã©ãŸãªãŠã
ååç©ãçšããŠæ°Žæ§æº¶æ¶²äžã®éå
æ§ç©è³ªããã³ã¹
ãŒããŒãªãã·ãã€ãªã³ã枬å®ããæ¹æ³ã®æäŸã§ã
ãã
ä»ã®ç®çã¯çäœäœæ¶²äžã®NADHãNADPHã«
ç¹ç°çã«æå©ãªæž¬å®æ¹æ³ã§ãããæ°Žæ§æº¶æ¶²ã®PHå€
åã«ãã圱é¿ãå°ããã枬å®æ©åšã®æ±æã®ãªãé
å
æ§ç©è³ªã®æž¬å®æ¹æ³ã«ããã
(ã) åé¡ç¹ã解決ããããã®æ段
æ¬çºæã®æ°èŠãªæ°Žæº¶æ§ãžããã©ãŸãªãŠã ååç©
ã¯ãäžè¬åŒ(1)ã§è¡šãããïŒ
åŒäžãR1ããã³R3ã¯æ°ŽçŽ ãR2ããã³R4ã¯åŒ
(2)ãŸãã¯(3)
ïŒåŒäžãããã³ïŒ¹ã¯SO2NHããã³R7ã¯æ°Ž
çŽ ãR6ããã³R8ã¯ã¹ã«ãã³é
žåºã瀺ããïŒã§è¡šã
ããåºãããã³ïŒ±ã¯æ°ŽçŽ ãã¯ããã²ã³ã瀺
ãã
ã¹ã«ãã³é
žåºã¯ãããã©ãŸãŒã«ç°ãšååå
å¡©ã
圢æããŠããã
æ¬çºæã®ããã©ãŸãªãŠã ååç©ã¯å
¬ç¥ã®åæã
æ¹æ³ã«ãã容æã«è£œé ããããšãã§ããã
äŸãã°ãïœâããããã³ãŒã³ã¹ã«ããã«ã¯ãã©
ã€ããšïœâã¢ãããã³ãŒã³ã¹ã«ãã³é
žãšã®çž®åç©
ãéå
ããŠåŸãããåŒ(4)
ã®ã¢ããååç©ãåžžæ³ã«ããããã©ãžã³ååç©ãš
ãã次ãã§ãäŸãã°ãã³ãºã¢ã«ããããšçž®åãã
ã°åŒ(5)
ã§ç€ºãããããšãã«ããã©ãŸã³ååç©ãåŸãã
ãã
ããã«ãïŒïŒ3â²âãžã¯ãããã³ãžãžã³ã®ããã©
ãŸååç©ãåžžæ³ã«ããã«ãããªã³ã°ãããããšã«
ãã€ãŠåŒ(6)
ã§ç€ºããããã«ãã¶ã³ååç©ãåŸãããã
åŸããããã«ãã¶ã³ååç©ãåžžæ³ã«ããé
žåã
ãã°ãç®çãšãããžããã©ãŸãªãŠã ååç©(7)
ãåŸãããšãã§ããã
æ¬çºæã®ãžããã©ãŸãªãŠã ååç©ã®è£œæ³ã¯ãåŸ
èšå®æœäŸã«è©³è¿°ãããŠããã
æ¬çºæã«ããããžãã«ãã¶ã³ååç©ã¯ãã¢ã«ã³
ãŒã«ç芪氎æ§ã®å€§ããææ©æº¶åªã«æ溶ã§ããã
ããé
žåã極ããŠåæ»ã§ããé
žåã«ãã€ãŠåŸãã
ããžããã©ãŸãªãŠã å¡©ååç©ã¯æ°Žäžååå
é å¡©ã«
ããé
žæ§äžã§ã¯ããé£æº¶ã®çµæ¶ãšããŠé«çŽåºŠã«å
åããããšãã§ããã«ã©ã 粟補çç¹éãªç²Ÿè£œã«ã
ãããšãæ¯èŒçé«çŽåºŠã®å質ã«ããããšãã§ã
ãããããã®ããã©ãŸãªãŠã ååç©ã¯æ°Žäžã匱ã¢
ã«ã«ãªæ§ãšããããšã«ãããå®çšäžå
åãªæ°Žæº¶æ§
ãæããã
æ¬çºæã®ç¬¬äºã®èŠæšã¯ãåèšäžè¬åŒ(1)ã§ç€ºãã
ã氎溶æ§ãžããã©ãŸãªãŠã ååç©ãçšãããšãç¹
城ãšããæ°Žæ§æº¶æ¶²äžã®éå
æ§ç©è³ªã®æž¬å®æ¹æ³ã«å
ããã
ãžããã©ãŸãªãŠã ååç©(1)ã¯ãéå
æ§ç©è³ªãäŸ
ãã°NADHãŸãã¯NADPHã®æ°ŽçŽ å容äœãšããŠ
äœçšãããããã¯ã¹ãŒããŒãªããµã€ãã€ãªã³ã«ã
ã€ãŠéå
ããããéå
ã®éã«å®éçã«çæããã
ã«ãã¶ã³ã®éã«æ¯äŸããçºè²ã®çšåºŠããåžå
å
床
枬å®æ³ã§æž¬å®ããããšã«ãã€ãŠãéå
æ§ç©è³ªã§ã
ãNADHãNADPHãŸãã¯ã¹ãŒããŒãªããµã€ã
ã€ãªã³ã®éã枬å®ããããšãã§ããããã®ãããª
枬å®æ¹æ³ã¯ãè±æ°ŽçŽ é
µçŽ ã®æŽ»æ§åºŠã®æž¬å®ãããã«
ããåºè³ªã®å®éãå³ã¡ãçäœæåãé£åäžã®æ·»å
ç©ãªã©ã®å®éã«æ¥µããŠæçšã§ããã
ãããã®åçããä¹³é
žè±æ°ŽçŽ é
µçŽ ïŒLDHïŒã®
掻æ§åºŠæž¬å®ã«äŸã«ãšã瀺ãã°æ¬¡ã®éãã§ããïŒ
ïŒNADïŒNADHã®é
žååïŒ
ãããã®åå¿ã®çµæå®éçã«çæãããã«ãã¶
ã³ã®æ¿åºŠããåžå
床枬å®ããããšã«ããå®éãã
ã°LDHã®æŽ»æ§åºŠã枬å®ããããšãã§ããã
åãè±æ°ŽçŽ é
µçŽ ã䜿çšããçäœæåã®æž¬å®ãã³
ã¬ã¹ãããŒã«ã®æž¬å®ã«ã€ããŠç€ºãã°æ¬¡ã®éãã§ã
ãïŒ
åæ§ã«ã³ã¬ã¹ãããŒã«ã®å®éãå¯èœã§ããã
æŽã«ãçäœæåäžã®ã¯ã¬ã¢ãã³çé
žãããŒãŒ
ïŒCPKïŒã«ã€ããŠç€ºãã°æ¬¡ã®éãã§ããïŒ
ïŒNADPïŒNADPHã®é
žåå
HKïŒãããœããŒãŒ
ADPïŒã¢ããã·ã³âïŒâçé
ž
ATPïŒã¢ããã·ã³âïŒâçé
ž
âïŒâPDHïŒã°ã«ã³ãŒã¹âïŒâçé
žè±æ°ŽçŽ
é
µçŽ ïŒ
åŸã€ãŠãåæ§ã«CPKã®æŽ»æ§åºŠã®æž¬å®ãå¯
èœã§ããã
ããã©ãŸãªãŠã ã®å¿çšã«ã€ããŠã¯ããã®ä»
çš®ã
ã®æ¹æ³ãããããããã¯äžèšå®æœäŸã«ã
ãæããã«ãããã
å®éã®æž¬å®ã«åœãã€ãŠã¯ãããªã¹çé
žç·©è¡
液ãªã©ã®é©å®ã®åªäœäžã«ãããŠã被æ€æ¶²ã«å®
é察象åºè³ªã«ç¹ç°çãªé
žåé
µçŽ ãè±æ°ŽçŽ é
µçŽ
ãªã©ã®é
µçŽ é¡ããã³äžè¬åŒ(1)ã§ç€ºããããžã
ãã©ãŸãªãŠã ååç©ãæ·»å ããã€ã³ããŠããŒ
ãããŠåå¿ãé²è¡ããããçºè²çæãããã«
ãã¶ã³ã®åžå
床ã枬å®ãã被æ€æ¶²äžã®éå
æ§
ç©è³ªãŸãã¯ã¹ãŒããŒãªããµã€ãã€ãªã³ããã
ã«ã¯åºè³ªãå®éããã
ã¹ãŒããŒãªããµã€ãã€ãªã³ã®å®éã®éã«ã¯
被æ€æ¶²äžã«ã枬å®æéãæ床ãå®éæ§ãªã©å®
çšçã«æž¬å®å¹æãããã«å©é·ãããããã«ã
åŸæ¥ãã䜿çšãããŠããããšããŒã«é¡ãããª
ããšããŒã«é¡ãã¢ãã³é¡ãªã©ãæ·»å ããŠãã
ããšãã§ããããŸã枬å®æã®å¥œãŸãããªãå¯
åå¿ã§ããèªåé
žåãé²æ¢ããããã«ãã¬ãŒ
ãå€ãå ããŠãããã
ãããã®æ·»å å©å€ã¯ãé©å®ãåç¬ãŸãã¯çµ
åãããŠçšãããããç¹ã«æ·»å å©å€ãšããŠç
é¢æŽ»æ§å€ã䜵çšããããšã¯ããã«ãã¶ã³åè²
ã®æ¥µå€§åžåãé·æ³¢é·åŽã«ã·ããããå¹æãã
ã€ãŠãåè²æ床ãããã«å¢å ãããã®ã§æ¬çº
æ枬å®æ¹æ³ã«ãããŠã¯å¥œãŸããæ
æ§ã§ããã
çé¢æŽ»æ§å€ãšããŠã¯ãèèªæãè³éŠæã¢ã«ã³
ãŒã«ã®ããªãªãã·ãšãã¬ã³èªå°äœã䜿çšã
ãããã®éå床ã¯ïŒã30çšåºŠãäžè¬çã§ã
ããäžè¬ã«åžè²©ãããŠãããããªã³ç³»çé¢æŽ»
æ§å€ãéåžžäžäŸ¿ãªã䜿çšã§ããã
枬å®äžã®è¢«æ€æ¶²ã®PHã¯ãéåžž7.0ã8.0ã®äž
æ§åã奜ãŸããããæ¬çºæã®æž¬å®æ¹æ³ã§ã¯PH
6.0ã10.5ã®ç¯å²ã«ãããŠãåè²æ床ã®å€å
ã¯å°ãªããé
žæ§åã§ãå€åã¯å°ããã
(ã) äœçšããã³å¹æ
æ¬çºæã®äžè¬åŒ(1)ã§ç€ºããããžããã©ãŸãª
ãŠã ååç©ããã³ãã®éå
äœãã«ãã¶ã³ã¯ã
ã¹ã«ãã³é
žåºïŒåãæãã眮æã¹ã«ãã¢ã¢ã€
ã«åºïŒåãæããããšã«ãã€ãŠæ°Žæº¶æ§ã®é倧
ãæå¶ããããšãã§ãã補é ã粟補ã容æã§
ããã
ãŸãéå
ããŠåŸããããã«ãã¶ã³ã®äžæ§ä»
è¿ã«ãããåžå
波圢ããåŸæ¥ã®ãã«ãã¶ã³ã«
æ¯èŒããŠé·æ³¢é·ïŒçŽ500nmïŒã§ããã®ã§ãäœ
液äžã®çè²æå450nmè¿èŸºãšåºå¥ãèããã
枬å®èª€å·®ãçãé£ãã
ãŸãæ¬çºæã®ãžããã©ãŸãªãŠã ååç©ãé
å
ãåããéã®PHäŸåæ§ã極ããŠå°ããã®ã§
枬å®çµæãåçŸæ§ããããããé«æ床ã«åŸã
ããã
èšåºæ€æ»åéã§ããããžããã©ãŸãªãŠã å
åç©ã䜿çšããŠåºè³ªãããã¯é
µçŽ 掻æ§åºŠã枬
å®ããæãçäœæåã«å
±åããçš®ã
ã®éå
æ§
ç©è³ªããŸãåæã«ããã©ãŸãªãŠã ååç©ãé
å
ããŠæž¬å®çµæã«æ£ã®èª€å·®ãäžããçµæãšãª
ãããã®åœ±é¿ãé€ãããã«ãããããããšãŠ
çŽ é
žã«ãªãŠã ãªã©ã®åŒ±ãé
žåå€ã§æ€äœïŒçäœ
æåïŒãååŠçããŠéå
æ§ç©è³ªãé€å»ãã
åŸãåºè³ªãããã¯é
µçŽ 掻æ§åºŠã®æž¬å®ããã
ããæ¬é¡çºæã®ãžããã©ãŸãªãŠã ååç©ã¯
NADHãNADPHã«ç¹ç°çãªäœçšæ§ãæãã
çäœæåã«å
±åããçš®ã
ã®éå
æ§ç©è³ªãååŠ
çå€ã«åœ±é¿ãããæ£ç¢ºãªæž¬å®æ
å ±ãåŸãããš
ãã§ããã
(ã) å®æœäŸ
以äžã«æ¬çºæãå®æœäŸããã³æ¯èŒäŸã«ãã
詳述ããããæ¬çºæã¯ãããå®æœäŸã«éå®ã
ãããã®ã§ã¯ãªãã
å®æœäŸ ïŒ
ããšãã«ããã©ãžã³âïŒâã¹ã«ãâ3â²âã¹
ã«ãã³é
žããšãã«ã¢ãã34ïœãæ°Ž1000mlã«æº¶
解ãããã³ãºã¢ã«ããã10.8ïœãå ããã次
ãã§ã40ã45âã§ïŒæéãããŸããåŸãå¡©æ
ããŠããã©ãŸã³ååç©ãåç70ïŒ
ã§åŸãã
åŸãããããã©ãŸã³ååç©2.3ïœãããœãŒ
ãç°ïŒïœãå«ãæ°Ž40mlã«æ·»å ããŠïŒã10âã§
溶解ããå¥ã«ïŒïŒ3â²âãžã¯ãããã³ãžã·ã³
0.63ïœãåžžæ³ã§ããã©ãŸã³åããPHãçŽïŒã«
調æŽãã液ãå ããã¢ã«ã«ãªæ§ã«ãããŠïŒæ
éãããŸããã®ã¡ãåŸããããžãã«ãã¶ã³å
åç©ãäžåãæ¶æããå¥ãããã¡ã¿ããŒã«ã«
ãã粟補ãããžãã«ãã¶ã³ååç©ã®ã±ãŒãïŒ
ïœãåŸãã
次ã«ã湯济äžäžèšãžãã«ãã¶ã³ååç©ã±ãŒ
ããã¡ã¿ããŒã«70mlã«æº¶è§£ãã70ã75âã§ïŒ
ïŒ
å¡©é
ž10ïœãå ãã次ãã§éç¡«é
žã¢ã³ã¢ããŠ
ã çµæ¶ïŒïœãå ããé
žåãçµäºãããŸã§70ã
75âã§çŽïŒæéãããŸããã掻æ§çãå ãã
ã®ã¡ãç±ãéããã液ãæ°Žã§300mlã«åžéã
ãŠæ¶æãããæåºããæ·¡é»çœè²çµæ¶ããé
ããå·æ°Žã§å
åæŽæµããã®ã¡ä¹Ÿç¥ãããæ·¡é»
çœè²ç²æ«1.3ïœãåŸãã
ãã®çæç©ã¯ã第ïŒå³ã«ç€ºããããªèµ€å€ç·
åžåæ²ç·åã³äžèšå
çŽ åæå€ãæããäžåŒã§
瀺ããããžããã©ãŸãªãŠã ååç©ã§ããã
å
çŽ åæå€ïŒïŒ
ïŒ
   
èšç®å€ 52.96 3.02 12.35 11.31
åæå€ 52.88 3.00 12.47 11.41
å®æœäŸ ïŒ
å®æœäŸïŒã®ããã©ãžã³ååç©ã®ä»£ããã«ã
äžèšåèäŸã«åŸã€ãŠåŸãããããšãã«ããã©
ãžã³âïŒâã¹ã«ãâ3â²âã¹ã«ãã³é
žããšãã«
ã¢ããã䜿çšãã以å€ã¯åæ§ã®åææ³ã«ã
ãã第ïŒå³ã«ç€ºããããªèµ€å€åžåæ²ç·åã³äž
èšå
çŽ åæå€ãæããäžåŒã§ç€ºããããžãã
ã©ãŸãªãŠã ååç©1.5ïœãåŸãã
å
çŽ åæå€
   
èšç®å€ 52.96 3.02 12.35 11.31
åæå€ 52.86 3.01 12.38 11.34
åèäŸ
ããšãã«ããã©ãžã³âïŒâã¹ã«ãâ3â²âã¹ã«ã
ã³é
žããšãã«ã¢ããã®è£œæ³ïŒ
ïŒâã¢ã»ãã«âã¢ãããã³ãŒã³âïŒâã¹ã«ãã
ã«ã¯ãã©ã€ã25ïœããïœâã¢ãããã³ãŒã³ã¹ã«ã
ã³é
ž18ïœãæ°Ž150mlã«ãœãŒãç°15ïœå
±åäžã«æº¶ã
ãã溶液äžã«20ã25âã§åŸã
ã«å ããïŒãïŒæé
ãããŸããã®ã¡ãå¡©é
žé
žæ§ãšããæåºç©ããéã
ããåŸãããã±ãŒããïŒïŒ
èæ§ãœãŒã150mläžã«
90ã95âã§ïŒæéåŠçããã®ã¡ãäžåããŠïŒâã¢
ãããã³ãŒã³âïŒâã¹ã«ãâ3â²âã¹ã«ãã³é
žããš
ãã«ã¢ãã氎溶液ãåççŽ70ïŒ
ã§åŸãã
以äžåžžæ³ã«ããåŸãããïŒâã¢ãããã³ãŒã³â
ïŒâã¹ã«ãâ3â²âã¹ã«ãã³é
žããšãã«ã¢ãããã
ãã©ãžã³ååç©ãšããã
次ã«ãäžèšå®æœäŸã«ãããŠåŸãããæ¬çºæã®å
åç©ãçšããNADHã«ããçºè²ãã¹ãåã³æ°Žæº¶
æ§ã®å®æœäŸã瀺ãã
å®æœäŸ ïŒãïŒ
å®æœäŸïŒããã³ïŒã§ãããããžããã©ãŸãªãŠã
ååç©ãããªãã³ïŒžâ405ïŒ0.4ïŒ
ãNAD2mMïŒ
ããžã¢ãã©ãŒãŒ2UïŒmlãå«æãã0.1Mããªã¹
çé
žç·©è¡æ¶²ïŒPH7.5ïŒïŒmlã«ã0.2mMïŒã«ãªã
ããå ããæ··åããæŽã«NADH2.8mMïŒãå«
ã氎溶液50ÎŒãå ãã35ã40âã§ïŒåéå æž©ã®
ããšãåžå
床ã枬å®ããã氎溶æ§ããã³çºè²æ§ã
次衚ã«ç€ºãã
(a) Industrial Application Field The present invention relates to a novel water-soluble ditetrazolium compound and a method for measuring reducing substances using the compound, and more specifically, 3,3'-(3,3'-dihalo-4, 4â²-diphenylene)-bis(2,5-
The present invention relates to a water-soluble ditetrazolium compound characterized by having one sulfonic acid group via a sulfamoyl group to the phenyl group of (diphenyl-2H-tetrazolium), and a method for measuring a reducing substance using the same. Tetrazolium compounds can be used to measure the activity of dehydrogenases, their substrates, and the substrates that act on oxidases that produce superoxide ions, in other words, to quantify additives in foods, or clinically analyze biological fluid components. It has been put into practical use as a reagent. (B) Prior art Since the water-soluble tetrazolium compound is a stable water-soluble compound, the formazan produced when it is reduced is used to measure reducing substances in an aqueous solution by quantifying this formazan. Ru. Conventional tetrazolium compounds include, for example, 2
-(4-phenyl iodide)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium salt (INT), 3-(4,5-dimethylthiazolyl-
2) -2,5-diphenyl-2H-tetrazolium salt (MTT), 2,2',5,5'-tetrakis(4-
Nitrophenyl)-3,3'-(3,3'-dimethoxy-4,4'-diphenylene)-2H,2'H-ditetrazolium salt (NTB), 2,2'-p-diphenylene-3,3',5,5'-tetraphenyl-2H,2'H-
Ditetrazolium salt (Neo-TB) is typically used. However, both of these tetrazolium salts and their reduced form, formazan, are sparingly soluble in water, and at present it is necessary to use a large amount of surfactant or organic solvent in combination. Particularly in the field of clinical testing, the generated formazan causes pigmentation in the photometric area of the measuring device, significantly affecting test results. Furthermore, with the rapid advancement of automation in testing in recent years, erroneous measurements may occur due to contamination of automatic analyzers. For the above reasons, even in the case of test items for which it is preferable to use a tetrazolium salt, it has been unavoidable to use other measurement principles. In response to this situation, Special Publication No. 56-38154,
Patent publications of JP-A-56-61366 and JP-A-56-61367, collection of lecture abstracts of the 102nd annual meeting of the Pharmaceutical Society of Japan, page 341, 4K2-
4 and others, attempts have been made to directly introduce a sulfonic acid group, a carboxylic acid group, or a side chain containing a quaternary ammonium salt into the phenyl group substituted on the tetrazole ring. However, due to these acid groups directly introduced into the phenyl group for the purpose of solubilization, within the optimal pH range where essential enzyme functions are exerted in actual measurements,
Since these tetrazolium compounds do not produce formazan, they are difficult to apply in the field of clinical testing.
Further, compounds into which quaternary ammonium salts are introduced are insufficient in terms of water solubility. Recently, as shown in JP-A-59-106476, attempts have been made to include two water-soluble groups (sulfonic acid groups and/or carboxylic acid groups) that are not directly bonded to the phenyl group. However, the molecular extinction coefficient of formazan, which is a reduced form of the tetrazolium compound proposed here, fluctuates significantly with changes in pH. In order to stop enzyme reactions, it is common in clinical tests to shift the pH of the reaction solution to acid or alkali, but when using the tetrazolium compound proposed here, it has the drawback of significantly reducing measurement sensitivity. have. (c) Problems to be Solved by the Invention The present inventors have found that in order to solve these conventional drawbacks, the tetrazolium compound should be easily water-soluble and should have low pH dependence when undergoing reduction. In particular, when used in clinical tests, it is specifically acted on by reduced nicotinamide adenine dinucleotide (hereinafter abbreviated as NADH) or reduced nicotinamide dinucleotide phosphate (hereinafter abbreviated as NADPH). As a result of their studies, they have completed the present invention, focusing on the fact that the produced formazan compound must be easily water-soluble. That is, the first object of the present invention is to provide a novel water-soluble tetrazolium compound that produces a readily water-soluble color-forming formazan in the presence of an electron transfer agent using a reducing substance. A second object of the present invention is to provide a method for measuring reducing substances and superoxide ions in an aqueous solution using a novel tetrazolium compound. Another purpose is to provide a method for measuring reducing substances that is specifically advantageous for NADH and NADPH in biological body fluids, is less affected by PH fluctuations in aqueous solutions, and does not contaminate measuring equipment. (d) Means for solving the problems The novel water-soluble ditetrazolium compound of the present invention is represented by general formula (1): [In the formula, R 1 and R 3 are hydrogen, R 2 and R 4 are the formula
(2) or (3) (In the formula, X and Y are SO 2 NH, R 7 is hydrogen, R 6 and R 8 are sulfonic acid groups.), P and Q are hydrogen, and Z is halogen. ] The sulfonic acid group forms an inner salt with the tetrazole ring. The tetrazolium compound of the present invention includes known raw materials,
It can be easily manufactured by this method. For example, the formula (4) obtained by reducing the condensate of m-tonylobenzenesulfonyl chloride and m-aminobenzenesulfonic acid If the amino compound of is converted into a hydrazine compound by a conventional method and then condensed with, for example, benzaldehyde, the formula (5) is obtained. A phenylhydrazone compound represented by is obtained. By coupling a tetrazo compound of 3,3'-dichlorobenzidine to this by a conventional method, formula (6) was obtained. A formazan compound represented by is obtained. By oxidizing the obtained formazan compound by a conventional method, the desired ditetrazolium compound (7) is obtained. can be obtained. The method for producing the ditetrazolium compound of the present invention is detailed in the Examples below. Since the diformazane compound used in the present invention is easily soluble in highly hydrophilic organic solvents such as alcohol, oxidation is extremely smooth, and the ditetrazolium salt compound obtained by oxidation is somewhat difficult to produce under acidic conditions due to intramolecular salt formation in water. It can be isolated with high purity as crystals of the solution, and relatively high purity quality can be obtained without complicated purification such as column purification. These tetrazolium compounds have sufficient water solubility for practical use by making them slightly alkaline in water. The second gist of the present invention resides in a method for measuring a reducing substance in an aqueous solution, which is characterized by using a water-soluble ditetrazolium compound represented by the general formula (1). The ditetrazolium compound (1) acts as a hydrogen acceptor for reducing substances, such as NADH or NADPH, or is reduced by superoxide ions. Measuring the amount of reducing substances NADH, NADPH, or superoxide ions by spectrophotometrically measuring the degree of color development that is proportional to the amount of formazan quantitatively produced during reduction. I can do it. Such a measurement method is extremely useful for measuring the activity of dehydrogenase and thereby quantifying substrates, that is, biological components, additives in foods, and the like. The following is an example of these principles when measuring the activity of lactate dehydrogenase (LDH): (NAD: Oxidized form of NADH) The activity of LDH can be measured by quantifying the concentration of formazan quantitatively produced as a result of these reactions by measuring absorbance. In addition, the measurement of biological components using dehydrogenase for cholesterol measurement is as follows: Similarly, cholesterol can be quantified. Furthermore, the following is shown regarding creatine phosphate kinase (CPK) in biological components: (NADP: oxidized form of NADPH HK: hexokase ADP: adenosine-2-phosphate ATP: adenosine-3-phosphate G-6-PDH: glucose-6-phosphate dehydrogenase) Therefore, CPK activity can be measured in the same way. is possible. There are various other methods for applying tetrazolium, which will be clarified by the examples below. In actual measurements, enzymes such as oxidases and dehydrogenases specific to the substrate to be quantified and enzymes expressed by general formula (1) are added to the test solution in an appropriate medium such as Tris phosphate buffer. A ditetrazolium compound is added thereto, the reaction is allowed to proceed by incubation, and the absorbance of the formazan produced is measured to quantify the reducing substance or superoxide ion, as well as the substrate, in the test solution. When quantifying superoxide ions, in order to further improve the practical measurement effect in terms of measurement time, sensitivity, quantitative performance, etc.,
Conventionally used phenols, thiophenols, amines, etc. can also be added. Furthermore, a chelating agent may be added to prevent autoxidation, which is an undesirable side reaction during measurement. These additive aids may be used alone or in combination as appropriate. In particular, the combined use of a surfactant as an additive auxiliary agent has the effect of shifting the maximum absorption of formazan coloring to the longer wavelength side, further increasing the coloring sensitivity, and is therefore a preferred embodiment in the measurement method of the present invention. .
As the surfactant, polyoxyethylene derivatives of aliphatic or aromatic alcohols are used, and the degree of polymerization thereof is generally about 5 to 30. Generally commercially available nonionic surfactants can be used without any inconvenience. The PH of the test liquid during measurement is normally preferably in the neutral range of 7.0 to 8.0, but in the measurement method of the present invention, the PH
There is little change in color sensitivity even in the range of 6.0 to 10.5, and even in the acidic range. (E) Action and Effect The ditetrazolium compound represented by the general formula (1) of the present invention and its reduced formazan,
By having two substituted sulfamoyl groups having one sulfonic acid group, excessive water solubility can be suppressed, and production and purification are easy. In addition, the absorption waveform of the formazan obtained by reduction near neutrality has a longer wavelength (approximately 500 nm) than that of conventional formazan, so it is markedly distinguishable from the colored components in body fluids around 450 nm.
Less likely to cause measurement errors. Further, since the ditetrazolium compound of the present invention has extremely low pH dependence upon reduction, measurement results can be obtained with good reproducibility and high sensitivity. When these ditetrazolium compounds are used to measure substrate or enzyme activity in the field of clinical testing, various reducing substances that coexist in biological components may also reduce the tetrazolium compounds, resulting in positive errors in the measurement results. becomes. In order to eliminate this effect, the specimen (biological component) is pretreated with a weak oxidizing agent such as potassium iodate to remove reducing substances, and then the substrate or enzyme activity is measured. Tetrazolium compounds are
It has specific action on NADH and NADPH,
Accurate measurement information can be obtained without being affected by various reducing substances and pretreatment agents that coexist with biological components. (F) Examples The present invention will be explained in detail below using Examples and Comparative Examples, but the present invention is not limited to these Examples. Example 1 34 g of phenylhydrazine-3-sulfo-3'-sulfonic acid phenylamide was dissolved in 1000 ml of water, and 10.8 g of benzaldehyde was added. Next, the mixture was stirred at 40 to 45°C for 2 hours and then salted out to obtain a hydrazone compound in a yield of 70%. 2.3 g of the obtained hydrazone compound was added to 40 ml of water containing 6 g of soda ash and dissolved at 5 to 10°C, and separately 3,3'-dichlorobenzicine was added.
0.63 g was tetrazonated using a conventional method, and a solution adjusted to a pH of about 5 was added, and after stirring in an alkaline environment for 7 hours, the obtained diformazan compound was neutralized, crystallized, and filtered. Purified with methanol, diformazan compound cake 7
I got g. Next, dissolve the above diformazan compound cake in 70 ml of methanol in a hot water bath, and heat it at 70 to 75°C for 70 minutes.
Add 10g of % hydrochloric acid, then add 2g of ammonium persulfate crystals, and simmer for 70~70 minutes until oxidation is complete.
Stir at 75â for about 2 hours. After adding activated carbon, the mixture was filtered under heat, and the filtrate was diluted with water to 300 ml for crystallization. The precipitated pale yellowish white crystals were filtered, thoroughly washed with cold water, and then dried. 1.3 g of pale yellowish white powder was obtained. This product is a ditetrazolium compound represented by the following formula and has an infrared absorption curve as shown in FIG. 1 and the following elemental analysis values. Elemental analysis value (%) C H N S Calculated value 52.96 3.02 12.35 11.31 Analysis value 52.88 3.00 12.47 11.41 Example 2 Instead of the hydrazine compound of Example 1,
The infrared absorption curve shown in Figure 2 and the following elemental analysis values were obtained by the same synthesis method except that phenylhydrazine-4-sulfo-3'-sulfonic acid phenylamide obtained according to the reference example below was used. 1.5 g of a ditetrazolium compound represented by the following formula was obtained. Elemental analysis value C H N S Calculated value 52.96 3.02 12.35 11.31 Analysis value 52.86 3.01 12.38 11.34 Reference Example: Process for producing phenylhydrazine-4-sulfo-3'-sulfonic acid phenylamide: 25 g of 1-acetyl-aminobenzene-4-sulfonyl chloride and 18 g of m-aminobenzenesulfonic acid were added to 150 ml of water in the presence of 15 g of soda ash. It is gradually added to the dissolved solution at 20-25°C, stirred for 5-6 hours, acidified with hydrochloric acid, and the precipitate is filtered. The resulting cake was dissolved in 150ml of 5% caustic soda.
After treatment at 90-95°C for 2 hours, it is neutralized to obtain an aqueous 1-aminobenzene-4-sulfo-3'-sulfonic acid phenylamide solution with a yield of about 70%. 1-Aminobenzene- obtained by the following conventional method
4-Sulfo-3'-sulfonic acid phenylamide is used as a hydrazine compound. Next, color development tests using NADH and water-solubility examples using the compounds of the present invention obtained in the above examples will be shown. Examples 3 to 4 The ditetrazolium compounds obtained in Examples 1 and 2 were mixed with Triton X-405, 0.4%, NAD 2mM/
, to 3 ml of 0.1 M Tris phosphate buffer (PH 7.5) containing 2 U/ml of diaphorase to give a concentration of 0.2 mM/ml, mix, add 50 Ό of an aqueous solution containing 2.8 mM/ml of NADH, and incubate at 35-40°C. After heating for 5 minutes, absorbance was measured. The water solubility and color development are shown in the table below.
ãè¡šã
æ¬çºæã®ãžããã©ãŸãªãŠã ååç©ã¯ãå®çšäžå
åãªæ°Žæº¶æ§ãæãããšãšãã«ãNADHâãžã¢ã
ã©ãŒãŒç³»ã®ãããªäœéå
é»äœç³»ã«ãããŠãè¯å¥œãª
çºè²ã瀺ããŠããã
å®æœäŸ ïŒ
å®æœäŸïŒã§åŸããžããã©ãŸãªãŠã ååç©
0.2mMïŒãããªãã³ïŒžâ405ïŒ0.4ïŒ
ãNAD
2mMïŒããžã¢ãã©ãŒãŒ2UïŒmlãå«æãã0.1M
ããªã¹çé
žç·©è¡æ¶²ïŒPH7.5ïŒïŒmlããšããäžæ¹ã
ããªãã³ïŒžâ405ãå ããªãåæ§ã®çµæã®ç·©è¡æ¶²
ïŒmlããšãã䞡液ã«NADH2.8mMïŒæ°Žæº¶æ¶²
50ÎŒãå ãã37âã§ïŒåéå æž©åŸãããããã®
åžå
ã¹ãã¯ãã«ã枬å®ãããçµæã第ïŒå³ã«ç€º
ãã
第ïŒå³ã«ç€ºãéããçé¢æŽ»æ§å€ã䜵çšããå Ž
åãå®æœäŸïŒã§åŸãæ¬çºæã®ãžããã©ãŸãªãŠã å
åç©ã§ã¯æ¥µå€§æ³¢é·520nmãã525nmã«ã·ãããã
ãã®åžå
床ã¯çŽïŒåã«å¢å€§ããã
次ã«ãæ¬çºæååç©ã«ããåè²ã®PHäŸåã®æ§å
ãNADHã®æž¬å®ãäŸã«ãšã€ãŠç€ºãã
å®æœäŸ ïŒ
ããªãã³ïŒžâ405ïŒ0.4ïŒ
ãå«æãã0.1Mããª
ã¹çé
žç·©è¡æ¶²ã«ãããŠãPHã5.8ã6.5ã7.0ã7.4ã
8.0ã8.4ã9.0ã9.4ã9.8ã10.5ã«èª¿è£œãã溶液ã
æºåããåã
ã«å®æœäŸïŒã§åŸãæ¬çºæãžããã©ãŸ
ãªãŠã ååç©0.2mMïŒããžã¢ãã©ãŒãŒ2UïŒml
ãå ãããã®æº¶æ¶²2.5mlã«NADH2.5mMïŒæ°Žæº¶
液50ÎŒãå ãã37âã§ïŒåéå æž©åŸãåPHã«ã
ããŠçæããããã«ãã¶ã³ã®æ¥µå€§åžå
床ãããã
ããããçµæã第ïŒå³ã«ç€ºãã
å³ã¡ãåè²ã®æ床ã¯å°ãªããšãPH7.2ã10.5ã«
ãããŠå€åã¯ãªããé
žæ§åã«ãããŠãå€åã¯èã
ãå°ãªãããã®ããšã¯NADHã®æž¬å®åã³åçš®è±
æ°ŽçŽ é
µçŽ ã®è³é©PHãèããåºç¯å²ã«äœ¿çšã§ããã
ãšãæå³ããåçŸæ§ãããå®å®ãã枬å®çµæãé«
æ床ã«åŸãããããšã«ãªãã
å®æœäŸïŒããã³æ¯èŒäŸïŒ
ããªãã³ïŒžâ405ïŒ0.4ïŒ
ãå«æãã0.1Mããª
ã¹çé
žç·©è¡æ¶²ïŒPH5.8ã7.5ã8.4ã9.0ã9.8ã«èª¿æŽïŒ
ã«å®æœäŸïŒã§åŸããžããã©ãŸãªãŠã ååç©ïŒå®æœ
äŸïŒïŒåã¯NTBïŒæ¯èŒäŸïŒïŒãå0.2mMïŒã
ãžã¢ãã©ãŒãŒ2UïŒmlã«ãªãããå ãåå¿æ¶²ã調
補ããããã®åå¿æ¶²2.5mlã«50mgïŒïœã¢ã¹ã³ã«
ãã³é
žæ°Žæº¶æ¶²50ÎŒãå ãã37âã§ïŒåéå æž©ã
ãŠãããçæãããããããã®ãã«ãã¶ã³ã®æ¥µå€§
åžå
床ã§åžå
床ã枬å®ããããã®çµæããããã
ããŠç¬¬ïŒå³ã®çµæãåŸãã
第ïŒå³ãããããããã«ãåŸæ¥äœ¿çšãããŠãã
NBTã«æ¯èŒããåPHã«ãããŠæ¬çºæã®ãžããã©
ãŸãªãŠã ååç©ã§ã¯çæããããã«ãã¶ã³ã¯èã
ãå°ãªãããã®ããšã¯ã¢ã¹ã³ã«ãã³é
žã«å¯Ÿãéå
ããé£ãããšã瀺ããNTBã«æ¯èŒãNADHã«å¯Ÿ
ããç¹ç°çã«äœçšããããšã®äžé¢ã瀺ããã®ã§ã
ãã
å®æœäŸ ïŒ
å®æœäŸïŒã§åŸãæ¬çºæãžããã©ãŸãªãŠã ååç©
1mMïŒãä¹³é
žãªããŠã å¡©25mMïŒã
NAD2mMïŒããžã¢ãã©ãŒãŒ2UïŒmlãEDTA
â2NalmMïŒããããªãã³ïŒžâ405ïŒ0.4ïŒ
ãå«
ã0.2Mããªã¹å¡©é
žç·©è¡æ¶²ïŒPH8.2ïŒã«å ããçºè²
詊液ãšããã
ããè¡æž
20ÎŒããšããçºè²è©Šè¬2.5mlãå ãã
37âã®ææž©ã§é£ç¶çã«çæããããã«ãã¶ã³ã®æ¥µ
倧åžå
床ã§ãã517nmã®åžå
床ã枬å®ãããçµæ
ã第ïŒå³ã«ç€ºãã
åãããè¡æž
ã20ã30ã40ÎŒãšå¢å ãããå
æ§ã«é£ç¶çã«åžå
床ã枬å®ããåŸãïŒåéåœãåž
å
床ã®å€åéãããããããŠç¬¬ïŒå³ã«ç€ºãçµæã
åŸãã
ãããã®çµæãããæ¬çºæã®æž¬å®æ¹æ³ã¯äœæ¶²æ
åã®æž¬å®ã«å¹æçã§ãå®éçãªåå¿ã§ããããšã
ãããã
次ã«ã¹ãŒããŒãªããµã€ãã®å®éã«ã€ããŠã³ã¬ã¹
ãããŒã«ã®å®éãäŸã«ãšã瀺ãã
å®æœäŸ ïŒ
å®æœäŸïŒã§åŸãååç©0.2mMïŒãã³ã¬ã¹ã
ããŒã«ãªãã·ããŒãŒ0.2UïŒmlããã«ãªãã·ããŒ
ãŒ10UïŒmlãâãšãã«ïŒïŒâããããã·âïŒâ
ã¹ã«ããªãããã«ïŒâïœâãã«ã€ãžã³1mMïŒã
éå
åã°ã«ã¿ããªã³0.5mMïŒããããªãã³ïŒž
â100ïŒ0.2ïŒ
ãå«ã0.1Mããªã¹å¡©é
žç·©è¡æ¶²ã«æº¶
解ããçºè²è©Šè¬ãšããã
ã³ã¬ã¹ãããŒã«ãã€ãœãããããŒã«ã«æº¶è§£ãã
300mgïŒïœã®æ¿åºŠã«èª¿è£œãè©Šæãšããã
è©Šæ10ã20ã30ã40ã50ÎŒãåã
åããçºè²
è©Šè¬ïŒmlãå ãã37âã®ææž©äžã§ïŒåéã€ã³ããŠ
ããŒãåŸãè©Šè¬ãã©ã³ã¯ã察ç
§ã«517nmã®åžå
床
ã枬å®ãããçµæã第ïŒå³ã«ç€ºãã
ãã®ããšã¯ãã³ã¬ã¹ãããŒã«ãªãã·ããŒãŒã®äœ
çšã«ããçæãããã¹ãŒããŒãªããµã€ãã€ãªã³ã
å®éçã«æž¬å®ã§ããããšã瀺ããã®ã§ããã[Table] The ditetrazolium compound of the present invention has sufficient water solubility for practical use, and also exhibits good color development in a low reduction potential system such as the NADH-diaphorase system. Example 5 Ditetrazolium compound obtained in Example 2
0.2mM/, Triton X-405, 0.4%, NAD
2mM/0.1M containing diaphorase 2U/ml
Take 3 ml of Tris phosphate buffer (PH7.5). on the other hand,
Take 3 ml of a buffer of similar composition without the addition of Triton X-405. NADH2.8mM/aqueous solution in both solutions
After adding 50Ό and heating at 37°C for 5 minutes, each absorption spectrum was measured. The results are shown in Figure 3. As shown in FIG. 3, when a surfactant is used in combination, the maximum wavelength of the ditetrazolium compound of the present invention obtained in Example 2 shifts from 520 nm to 525 nm.
Its absorbance increases approximately twice. Next, the PH dependence of color development by the compound of the present invention will be shown using the measurement of NADH as an example. Example 6 In 0.1M Tris phosphate buffer containing 0.4% Triton
8.0, 8.4, 9.0, 9.4, 9.8, and 10.5 were prepared, each containing 0.2 mM/ml of the ditetrazolium compound of the present invention obtained in Example 2 and 2 U/ml diaphorase.
was added, and 50Ό of a 2.5mM NADH/aqueous solution was added to 2.5ml of the solution, and after heating at 37°C for 5 minutes, the maximum absorbance of formazan produced at each pH was plotted. The results are shown in Figure 4. That is, there is no change in color sensitivity at least in the pH range of 7.2 to 10.5, and there is very little change in the acidic range. This means that the measurement of NADH and the optimum pH of various dehydrogenases can be used over a significantly wide range, and stable measurement results with good reproducibility and high sensitivity can be obtained. Example 7 and Comparative Example 1 0.1M Tris phosphate buffer containing 0.4% Triton X-405 (adjusted to PH5.8, 7.5, 8.4, 9.0, 9.8)
0.2mM/each of the ditetrazolium compound (Example 7) or NTB (Comparative Example 1) obtained in Example 2,
Add diaphorase to a concentration of 2 U/ml to prepare a reaction solution. 50Ό of a 50mg/d ascorbic acid aqueous solution was added to 2.5ml of this reaction solution, heated at 37°C for 5 minutes, and the absorbance was measured at the maximum absorbance of each formazan produced.The results were plotted and We obtained the results shown in the figure. As can be seen from Figure 5, the conventionally used
Compared to NBT, the ditetrazolium compound of the present invention produces significantly less formazan at each pH. This shows that it is difficult to reduce ascorbic acid and shows that it acts specifically on NADH compared to NTB. Example 8 Ditetrazolium compound of the present invention obtained in Example 1
1mM/, lactate lithium salt 25mM/,
NAD 2mM/, diaphorase 2U/ml, EDTA
-2NalmM/ is added to 0.2M Tris-HCl buffer (PH8.2) containing 0.4% Triton X-405 to prepare a coloring reagent. Take 20Ό of human serum, add 2.5ml of coloring reagent,
The absorbance at 517 nm, which is the maximum absorbance of formazan continuously produced at a constant temperature of 37°C, was measured. The results are shown in Figure 6. Further, after increasing the amount of human serum to 20, 30, and 40Ό, and measuring the absorbance continuously in the same manner, the change in absorbance per minute was plotted to obtain the results shown in FIG. These results show that the measuring method of the present invention is effective in measuring body fluid components and is a quantitative reaction. Next, the determination of superoxide will be explained using the determination of cholesterol as an example. Example 9 0.2mM of the compound obtained in Example 1, cholesterol oxidase 0.2U/ml, peroxidase 10U/ml, N-ethyl (2-hydroxy-3-
sulfopropyl)-m-toluidine 1mM/,
Reduced glutathione 0.5mM/Triton
-100, dissolve in 0.1M Tris-HCl buffer containing 0.2% and use as a coloring reagent. Dissolve cholesterol in isopropanol,
Prepare the concentration to 300mg/d and use it as a sample. Samples 10, 20, 30, 40, and 50Ό were each taken, 5 ml of coloring reagent was added thereto, and after incubation at a constant temperature of 37°C for 5 minutes, the absorbance at 517 nm was measured using a reagent blank as a control. The results are shown in FIG. This shows that superoxide ions generated by the action of cholesterol oxidase can be quantitatively measured.
第ïŒå³ããã³ç¬¬ïŒå³ã¯ãå®æœäŸïŒããã³ïŒã§åŸ
ããžããã©ãŸãªãŠã ååç©ã®èµ€å€åžåã¹ãã¯ã
ã«ã第ïŒå³ã¯ãå®æœäŸïŒã§åŸãããåžå
ã¹ãã¯ã
ã«ã第ïŒå³ã¯ãå®æœäŸïŒã§åŸãããåžå
床ã瀺ã
å³ã第ïŒå³ã¯ãå®æœäŸïŒã§åŸãããåžå
床ã瀺ã
å³ã第ïŒå³ããã³ç¬¬ïŒå³ã¯ãå®æœäŸïŒã§åŸããã
åžå
床ã瀺ãå³ãããã³ç¬¬ïŒå³ã¯ãå®æœäŸïŒã§åŸ
ãããåžå
床ã瀺ãå³ã§ããã
Figures 1 and 2 are infrared absorption spectra of the ditetrazolium compounds obtained in Examples 1 and 2, Figure 3 is the absorption spectrum obtained in Example 5, and Figure 4 is the absorption spectrum of the ditetrazolium compounds obtained in Example 6. Figure 5 is a diagram showing the absorbance obtained in Example 7, Figures 6 and 7 are diagrams showing the absorbance obtained in Example 8, and Figure 8 is a diagram showing the absorbance obtained in Example 8. is a diagram showing the absorbance obtained in Example 9.
Claims (1)
(2)ãŸãã¯(3) ïŒåŒäžãããã³ïŒ¹ã¯SO2NHãR5ããã³R7ã¯
æ°ŽçŽ ãR6ããã³R8ã¯ã¹ã«ãã³é žåºã瀺ããïŒ ã§è¡šãããåºãããã³ïŒ±ã¯æ°ŽçŽ ãã¯ããã²ã³
ã瀺ããã§è¡šãããæ°èŠæ°Žæº¶æ§ãžããã©ãŸãªãŠ
ã ååç©ã ïŒ äžè¬åŒ(1) åŒäžãR1ããã³R3ã¯æ°ŽçŽ ãR2ããã³R4ã¯åŒ
(2)ãŸãã¯(3) ïŒåŒäžãããã³ïŒ¹ã¯SO2NHãR5ããã³R7ã¯
æ°ŽçŽ ãR6ããã³R8ã¯ã¹ã«ãã³é žåºã瀺ããïŒ ã§è¡šãããåºãããã³ïŒ±ã¯æ°ŽçŽ ãã¯ããã²ã³
ã瀺ããã§è¡šããã氎溶æ§ããã©ãŸãªãŠã åå
ç©ãçšããããšãç¹åŸŽãšããæ°Žæ§æº¶æ¶²äžã®éå æ§
ç©è³ªã®æž¬å®æ¹æ³ã ïŒ éå æ§ç©è³ªãéå åãã³ãã³é žã¢ããã¢ãã
ã³ãžãã¯ã¬ãªããåã¯éå åãã³ãã³é žã¢ãããž
ãã¯ã¬ãªããçé žã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«
èšèŒã®æž¬å®æ¹æ³ã ïŒ éå æ§ç©è³ªãã¹ãŒããŒãªããµã€ãã€ãªã³ã§ã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®æž¬å®æ¹æ³ã ïŒ ããã©ãŸãªãŠã ååç©ãçé¢æŽ»æ§å€ãšäœµçšã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒãïŒé ã®ããããã«èšèŒã®
枬å®æ¹æ³ã ïŒ æ°Žæ§æº¶æ¶²äžã®éå æ§ç©è³ªã枬å®ããããšã«ã
ã€ãŠæ°Žæ§æº¶æ¶²äžã®æåãå®éããç¹èš±è«æ±ã®ç¯å²
第ïŒãïŒé ã®ããããã«èšèŒã®æž¬å®æ¹æ³ã ïŒ æ°Žæ§æº¶æ¶²äžã®æåãçäœäœæ¶²äžã®æåã§ãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®æž¬å®æ¹æ³ã[Claims] 1 General formula (1) [In the formula, R 1 and R 3 are hydrogen, R 2 and R 4 are the formula
(2) or (3) (In the formula, X and Y are SO 2 NH, R 5 and R 7 are hydrogen, R 6 and R 8 are sulfonic acid groups.) P and Q are hydrogen, and Z is halogen. . ] A novel water-soluble ditetrazolium compound represented by: 2 General formula (1) [In the formula, R 1 and R 3 are hydrogen, R 2 and R 4 are the formula
(2) or (3) (In the formula, X and Y are SO 2 NH, R 5 and R 7 are hydrogen, R 6 and R 8 are sulfonic acid groups.) P and Q are hydrogen, and Z is halogen. . ] A method for measuring a reducing substance in an aqueous solution, characterized by using a water-soluble tetrazolium compound represented by the following. 3. The measuring method according to claim 2, wherein the reducing substance is reduced nicotinamide adenine dinucleotide or reduced nicotinamide dinucleotide phosphoric acid. 4. The measuring method according to claim 2, wherein the reducing substance is a superoxide ion. 5. The measuring method according to any one of claims 2 to 4, in which a tetrazolium compound is used in combination with a surfactant. 6. The measuring method according to any one of claims 2 to 5, wherein a component in an aqueous solution is quantified by measuring a reducing substance in the aqueous solution. 7. The measuring method according to claim 6, wherein the component in the aqueous solution is a component in a biological body fluid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27013184A JPS61148170A (en) | 1984-12-20 | 1984-12-20 | Water-soluble tetrazolium compound and method of measuring reducing substance using same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27013184A JPS61148170A (en) | 1984-12-20 | 1984-12-20 | Water-soluble tetrazolium compound and method of measuring reducing substance using same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61148170A JPS61148170A (en) | 1986-07-05 |
JPH0413352B2 true JPH0413352B2 (en) | 1992-03-09 |
Family
ID=17481982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP27013184A Granted JPS61148170A (en) | 1984-12-20 | 1984-12-20 | Water-soluble tetrazolium compound and method of measuring reducing substance using same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61148170A (en) |
-
1984
- 1984-12-20 JP JP27013184A patent/JPS61148170A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS61148170A (en) | 1986-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0124909B1 (en) | Process for determining reduced form coenzymes | |
JPS60184400A (en) | Novel color reagent | |
US4824779A (en) | Method for the determination of the reduced form of nicotinamide adenine dinucleotide | |
EP0488756B1 (en) | Oxidizable color producing reagent | |
JP2590124B2 (en) | Water-soluble tetrazolium compound and method for measuring reducing substance using the compound | |
JP5327578B2 (en) | Method for measuring phosphatase | |
JP2838866B2 (en) | Method for suppressing the activity of reducing substances in oxidative colorimetric analysis | |
JPH0571239B2 (en) | ||
JP2516381B2 (en) | Method for quantifying hydrogen peroxide and reagent for quantifying the same | |
US4695539A (en) | Process for quantitative determination of substrate treated with oxidase | |
JPH0413352B2 (en) | ||
JPH0413351B2 (en) | ||
JPH02276595A (en) | Method for measuring bile acid in high sensitivity and composition for measuring bile acid | |
Shiga et al. | Synthesis of a new tetrazolium salt giving a water-soluble formazan and its application in the determination of lactate dehydrogenase activity | |
JPS59106476A (en) | Water-soluble tetrazolium compound and a method for determining reductive substance using the same | |
US5792619A (en) | Assay using oxidative chromogenic reagent | |
JPS6240300A (en) | Activity measurement of adenosine deaminase in humor | |
JPS6219100A (en) | Measurement of bile acid | |
JPH0343096A (en) | Determination of substrate or enzyme | |
JPS61174267A (en) | Novel imidazole derivative and measuring method using same as color forming component | |
JPS62244397A (en) | Novel measurement of choline esterase activity | |
JPH02100699A (en) | Measurement of organism sample | |
JPH0362400B2 (en) | ||
JPH0432987B2 (en) | ||
JPS6036755B2 (en) | Method for measuring components in biological fluids |